Malin acquires Swiss biotech company Cilatus BioPharma AG

Founded in 2014 in Sarnen (OW), by Johannes Roebers, Cilatus Biopharma AG focuses on strategic and operational consulting services in Chemistry, Manufacturing, and Controls (CMC) /Technical Development, Good Manufacturing Practice (GMP), Regulatory Affairs, Quality Control/Assurance, Supply Chain, Engineering, Validation/Qualification and Manufacturing for biological products.

Cilatus possesses significant advisory and operating capability with industry experienced expert consultants with broad expertise for worldwide clients. Its team advises and supports operationally mainly small and medium sized biopharma companies and has established a successful track record from developing investigation New Drug Applications (INDs), Investigational Medicinal Product Dossier (IMPDs), to contract manufacturing organization (CMO) management, Phase I to Phase III development and manufacturing into supporting Biologic License Applications (BLA) or Marketing Authorization Applications (MAA) filings, commercial operations and supply chains.

By acquiring a significant ownership stake in Cilatus, Malin gains access to often mission critical CMC, manufacturing and GMP expertise of Cilatus and can participate directly in this aspect of the industry value chain. The Cilatus capability further enables Malin to accurately assess potential CMC and manufacturing challenges and thus creating opportunities to unlock value for the operating companies with whom Malin works with.

Under the terms of the transaction, Johannes Roebers, will join the Executive Team of Malin reporting to Kelly Martin, CEO. In his Malin role, Johannes will work closely with the team on existing companies and will be involved in assessing new business opportunities for Malin. In addition, Johannes will continue to manage the Cilatus business on a day-to-day basis with his team of consultants.

Roebers earned a Ph.D. in Chemical Engineering from Clemson University, SC, USA and a Dipl.-Ing of RWTH Aachen, Germany and has over 25 years operational and strategic leadership experience, in the areas of CMC Development, GMP Manufacturing, Complex Manufacturing Facilities Development, Business Strategy and Risk Management, Regulatory Affairs, Clinical Operations, and Facilities/Engineering with major positions held at leading biopharmaceutical companies in Ireland, Germany, Canada and the US.

(Press release)